Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantation

Pharmacotherapy

Volumn 33, Issue 9, 2013, Pages 893-901

  Uchida, Mayako ^a   Kato, Koji ^b   Ikesue, Hiroaki ^a   Ichinose, Kimiko ^a   Hiraiwa, Hiromi ^a   Sakurai, Asako ^b   Muta, Tsuyoshi ^b   Takenaka, Katsuto ^b   Iwasaki, Hiromi ^a   Miyamoto, Toshihiro ^b   Teshima, Takanori ^a   Shiratsuchi, Motoaki ^b   Suetsugu, Kimitaka ^a   Nagata, Kenichiro ^a   Egashira, Nobuaki ^a   Akashi, Koichi ^b   Oishi, Ryozo ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Allogeneic stem cell transplantation; Aprepitant; High dose chemotherapy; Vomiting

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; GRANISETRON; MELPHALAN; METHOTREXATE; TACROLIMUS;

ABDOMINAL PAIN; ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACKACHE; BLOODSTREAM INFECTION; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSURIA; ENGRAFTMENT; FEMALE; FEVER; HEADACHE; HICCUP; HOT FLUSH; HUMAN; HYPERSENSITIVITY; INSOMNIA; JAPAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICAL RECORD REVIEW; MORNING DOSAGE; MYALGIA; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NEUTROPHIL ENGRAFTMENT; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PLATELET ENGRAFTMENT; RASH; SURVIVAL RATE; SURVIVAL TIME; T CELL LEUKEMIA; TREATMENT DURATION; TREMOR; UNIVERSITY HOSPITAL; VIRUS INFECTION; WHOLE BODY RADIATION;

ALLOGENEIC STEM CELL TRANSPLANTATION; APREPITANT; HIGH-DOSE CHEMOTHERAPY; VOMITING;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GRANISETRON; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; VOMITING;

EID: 84885336717     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1294     Document Type: Article

References (42)

1. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008;358:2482-94
2. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011;29:4189-98
3. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Antiemesis V.1.2012. Available from http://www.nccn.org/ professionals/physician-gls/pdf/antiemesis.pdf. Accessed August 31, 2012
4. Einhorn LH, Grunberg SM, Rapoport B, et al. Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 2011;19(Suppl 1):S1-4
5. Yen CC, Hsieh RK, Chiou TJ, et al. Navoban (tropisetron, ICS 205-930) and dexamethasone combination in the prevention of vomiting for patients receiving preconditioning high-dose chemotherapy before marrow transplantation. Jpn J Clin Oncol 1998;28:129-33
6. Climent MA, Palau J, Ruiz A, et al. The antiemesis efficacy of granisetron plus dexamethasone, haloperidol and lorazepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support. Support Care Cancer 1998;6:287-90
7. Osowski CL, Dix SP, Lynn M, et al. An open-label dose comparison study of ondansetron for the prevention of emesis associated with chemotherapy prior to bone marrow transplantation. Support Care Cancer 1998;6:511-7
8. Barbounis V, Koumakis G, Hatzichristou H, Vassilomanolakis M, Tsoussis S, Efremidis A. The anti-emesis efficacy of tropisetron plus dexamethasone in patients treated with high-dose chemotherapy and stem cell transplantation. Support Care Cancer 1999;2:79-83
9. Abbott B, Ippoliti C, Hecth D, Bruton J, Whaley B, Champlin R. Granisetron (Kytril) plus dexamethasone for antiemesis control in bone marrow transplant patients receiving highly emetogenic chemotherapy with or without total body irradiation. Bone Marrow Transplant 2000;25:1279-83
10. Ballen KK, Hesketh AM, Heyes C, et al. Prospective evaluation of antiemesis outcome following high-dose chemotherapy with hematopoietic stem cell support. Bone Marrow Transplant 2001;28:1061-6
11. Matsuoka S, Okamoto S, Watanabe R, et al. Granisetron plus dexamethasone vs granisetron alone in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study. Int J Hematol 2003;77:86-90
12. Walsh T, Morris AK, Holle LM, et al. Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, doubleblind, randomized trial. Bone Marrow Transplant 2004;34: 963-8
13. Trigg ME, Inverso DM. Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemesis regimens. Bone Marrow Transplant 2008;42:501-6
14. de Wit R, Herrstedt J, Rapoport B, et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003;21:4105-11
15. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, doubleblind, placebo-controlled trial in Latin America. Cancer 2003;97:3090-8
16. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-30
17. Bubalo JS, Leis LF, Curtin PT, et al. A randomized, doubleblinded, pilot trial of aprepitant added to standard antiemetics during conditioning therapy for hematopoietic stem cell transplant (HSCT). J Clin Oncol 2007;25(18S):9112
18. Paul B, Trovato JA, Thompson J, Badros AZ, Goloubeva O. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. J Oncol Pharm Pract 2010;16:45-51
19. Jordan K, Jahn F, Jahn P, et al. The NK-1 receptor-antagonist aprepitant in high-dose (HD) chemotherapy (HD melphalan and HD T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemesis combination. Bone Marrow Transplant 2011;46:784-9
20. Stiff PJ, Fox-Geiman MP, Kiley K, et al. Prevention of nausea and vomiting associated with stem cell transplantation: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant 2013;19:49-55
21. Pielichowski W, Barzal J, Gawronski K, et al. A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. Transplant Proc 2011;43:3107-10
22. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:1813-26
23. Majumdar AK, McCrea JB, Panebianco DL, et al. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther 2003;74:150-6
24. Aapro MS, Walko CM. Aprepitant: drug-drug interactions in perspective. Ann Oncol 2010;21:2316-23
25. Glotzbecker B, Duncan C, Alyea E 3rd, Campbell B, Soiffer R. Important drug interactions in hematopoietic stem cell transplantation: what every physician should know. Biol Blood Marrow Transplant 2012;18:989-1006
26. Ono Pharmaceutical. EMEND (aprepitant) package insert. Osaka, Japan; 2012
27. Bubalo JS, Cherala G, McCune JS, Munar MY, Tse S, Maziarz R. Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation. J Clin Pharmacol 2012;52:586-94
28. Egerer G, Eisenlohr K, Gronkowski M, Burhenne J, Riedel KD, Mikus G. The NK receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. Br J Clin Pharmacol 2010;70:903-7
29. de Jonge ME, Huitema AD, Holtkamp MJ, et al. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol 2005;56:370-8
30. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-8
31. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-vs-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-56
32. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994;12:1169-76
33. Ohtake S, Miyawaki S, Fujita H, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: JALSG AML201 Study. Blood 2011;117:2358-65
34. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896-903
35. Uchida M, Ikesue H, Kato K, et al. Efficacy and safety of aprepitant in patients with hematologic malignancies receiving multiday chemotherapy. Am J Health Syst Pharm 2013;70:343-9
36. Ibrahim RB, Abidi MH, Ayash LJ, et al. Effect of aprepitant on intravenous tacrolimus disposition in reduced intensity hematopoietic stem cell transplantation. J Oncol Pharm Pract 2008;14:113-21
37. Pielichowski W, Gawronski K, Mlot B, et al. Triple drug combination in the prevention of nausea and vomiting following busulfan plus cyclophosphamide chemotherapy before allogeneic hematopoietic stem cell transplantation. J BUON 2011;16:541-6
38. Yamamoto K, Nohara K, Furuya T, Yamatodani A. Ondansetron, dexamethasone and an NK1 antagonist block radiation sickness in mice. Pharmacol Biochem Behav 2005;82:24-9
39. Furue H, Oota K, Taguchi T, Niitani H. Clinical evaluation of granisetron against nausea and vomiting induced by anticancer drugs (1) [in Japanese]. J Clin Ther Med 1990;5:49-61
40. Chugai Pharmaceutical. Kytril (granisetron) package insert. Tokyo, Japan; 2011
41. Musso M, Scalone R, Crescimanno A, et al. Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. Bone Marrow Transplant 2010;45:123-7
42. Giralt SA, Mangan KF, Maziarz RT, et al. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann Oncol 2011;22:939-46